Takeda Confident As Dengue Vaccine Shows Benefits Three Years Out
Protection Regardless Of Prior Infection
Executive Summary
New long-term Phase III data for Takeda's candidate dengue vaccine show continued protection against illness and hospitalization, regardless of previous exposure, out to the three-year mark following the two-dose jab.
You may also be interested in...
Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
Positive Evidence Stacks Up For Takeda's Dengue Vaccine
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.